Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
VIPoma other imaging findings
Introduction
Overview
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan using radiolabeled somatostatin analogs.
Other Imaging Findings
Other Imaging Findings
- Somatostatin receptor scintigraphy (Octreoscan) is used to localize the tumor, which is usually metastatic at presentation.[1][2][3]
- Functional PET scan is also used to diagnose somatostatin receptor positive neuroendocrine tumors.
- Nearly 80-90% of all VIPoma are somatostatin receptor positive.
References
References
- ↑ Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T (2014). “Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male”. Hematol Oncol Stem Cell Ther. 7 (3): 109–15. doi:10.1016/j.hemonc.2014.03.002. PMID 24785507.
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). “MSH2 and CXCR4 involvement in malignant VIPoma”. World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.
- ↑ Virgolini, I.; Patri, P.; Novotny, C.; Traub, T.; Leimer, M.; Fuger, B.; Li, S. R.; Angelberger, P.; Raderer, M.; Wogritsch, S.; Kurtaran, A.; Kletter, K.; Dudczak, R. (2001). “Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy”. Annals of Oncology. 12 (suppl 2): S41–S45. doi:10.1093/annonc/12.suppl_2.S41. ISSN 0923-7534.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]